The clinical research for Jiedu Qingnao granules additional treatment on first episode schizophrenia

Not Applicable

Recruiting

• Conditions: Schizophrenia

• Registration Number: ITMCTR1900002841
• Lead Sponsor: Beijing Anding Hospital, Capital Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. meet the criteria for the study of first episode schizophrenia;
2. Aged between 18 and 40 years (including 18 and 40);
3. Sign the informed consent and be able to comply with the research scheme;
4. Understand the follow-up questionnaire survey;
5. Meet the criteria of the standard of traditional Chinese medicine syndromes of damage of brain collateral by toxin (hallucinations, delusions, weird thinking, thinking lax, looseness of thought, stunned and speechless, automatic speaking and laughing, solitude, dry mouth, constipation, red tongue, yelow coating of the tongue, pulse string slide).

Exclusion Criteria

1. Have severe suicidal tendencies;
2. Be in a depressive episode;
3. With serious or unstable heart, liver, kidney, endocrine, blood and other medical diseases;
4. Be treated with antipsychotic medications within 4 weeks;
5. Unattended;
6. Compared to baseline, the reduction rate of PANSS scale screening score is more than 25%.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
symptoms assessment;

Secondary Outcome Measures

Name	Time	Method
assessment of adverse reaction;BDNF,TNFa\IL-6\IL-1ß;assessment of cognition function;